Brainstorm Cell Therapeutics (BCLI) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

BCLI Brainstorm Cell Therapeutics

Watchlist

0.532
-0.013-2.39%

Close Apr 25 16:00 ET

0.515
-0.017-3.16%

Post 18:26 ET

36.36MMarket Cap-1330P/E (TTM)

Post-Market

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Brainstorm Cell Therapeutics Executive Leadership Changes
TipRanksApr 17 06:12 ET
BrainStorm Cell Therapeutics Promotes Bob Dagher to Chief Medical Officer
Seeking AlphaApr 17 03:25 ET
Express News | Reported Earlier, BrainStorm Cell Therapeutics Announces Management Changes As It Plans Registrational Phase 3b Trial Of NurOwn
Moomoo 24/7Apr 17 02:54 ET
BrainStorm Cell Therapeutics Loses Co-CEO Lindborg, Names Dagher as New Medical Chief
By Ben Glickman BrainStorm Cell Therapeutics named a new medical chief and said Co-Chief Executive Stacy Lindborg would step down ahead of a long-awaited clinical trial. The New York-based company,
WSJApr 16 18:51 ET
BrainStorm Cell Therapeutics: Bob Dagher, MD, Promoted to Chief Medical Officer >GHDN.BE
BrainStorm Cell Therapeutics: Bob Dagher, MD, Promoted to Chief Medical Officer >GHDN.BE
Dow JonesApr 16 18:33 ET
Express News | Brainstorm Cell Therapeutics Inc - Stacy Lindborg Stepping Down as Co-CEO and Transitioning to Board of Directors
Moomoo 24/7Apr 16 18:31 ET

Comments

Claudine101

Apr 12 00:27

$Brainstorm Cell Therapeutics(BCLI.US)$ why is it going down with all the good news 🤔

Trytosaveabit

Apr 11 18:01

Nice!

$Brainstorm Cell Therapeutics(BCLI.US)$ Brainstorm Cell Therapeutics Regains Compliance With Nasdaq Minimum Market Value Rule

Double_Bottom

Apr 10 22:43

$Brainstorm Cell Therapeutics(BCLI.US)$ need more volume on good news.....waiting for liftoff

Trytosaveabit

Apr 10 18:04

$Brainstorm Cell Therapeutics(BCLI.US)$ BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS NurOwn treatment resulted in a positive impact on important CSF biomarkers relevant to ALS compared to placebo. Significant changes in multiple ALS disease pathways support NurOwn's mechanism of action and complement clinical effects observed in ALS.